1. Home
  2. BCO vs ABCL Comparison

BCO vs ABCL Comparison

Compare BCO & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Brinks Company (The)

BCO

Brinks Company (The)

N/A

Current Price

$116.78

Market Cap

4.2B

ML Signal

N/A

Logo AbCellera Biologics Inc.

ABCL

AbCellera Biologics Inc.

N/A

Current Price

$11.58

Market Cap

4.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BCO
ABCL
Founded
1859
2012
Country
United States
Canada
Employees
125
N/A
Industry
Oil Refining/Marketing
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.2B
4.1B
IPO Year
2010
2020

Fundamental Metrics

Financial Performance
Metric
BCO
ABCL
Price
$116.78
$11.58
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
13
Target Price
★ $145.33
$18.00
AVG Volume (30 Days)
506.8K
★ 3.2M
Earning Date
11-04-2026
11-09-2026
Dividend Yield
★ 0.87%
N/A
EPS Growth
★ 29.20
10.91
EPS
★ 2.19
N/A
Revenue
★ $3,562,300,000.00
$75,128,000.00
Revenue This Year
$5.10
N/A
Revenue Next Year
$3.37
$10.03
P/E Ratio
$53.34
★ N/A
Revenue Growth
N/A
★ 160.56
52 Week Low
$91.05
$2.75
52 Week High
$136.37
$14.98

Technical Indicators

Market Signals
Indicator
BCO
ABCL
Relative Strength Index (RSI) 63.86 45.51
Support Level $107.15 $10.65
Resistance Level $124.32 $13.21
Average True Range (ATR) 5.15 1.00
MACD 1.06 -0.06
Stochastic Oscillator 84.91 25.16

Price Performance

Historical Comparison
BCO
ABCL

About BCO Brinks Company (The)

The Brink's Co is a provider of secure logistics and security solutions for cash and other valuables. Its segments include: North America segment includes operations in the U.S. and Canada, including the Brink's Global Services (BGS) line of business; Latin America segment consists operations in Latin American countries where it has an ownership interest, including the BGS line of business; Europe segment includes total operations in European countries that provide services outside of the BGS line of business; and Rest of World segment consists operations in the Middle East, Africa and Asia. It also includes total operations in European countries that provide BGS services and BGS activity in Latin American countries. It derives maximum revenue from the North America segment.

About ABCL AbCellera Biologics Inc.

AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.

Share on Social Networks: